Accession Number : ADA606936


Title :   The AMIGO Clinical Study: Attrition Rates Among Military Beneficiaries Undergoing Intensive Group Outpatient Pre-Diabetes Care


Descriptive Note : Final rept. 1 Apr 2011-19 Jul 2013


Corporate Author : AIR FORCE MEDICAL GROUP (779TH) JOINT BASE ANDREWS MD


Personal Author(s) : Nokuri, Samuel S ; Dean, Jennifer ; Price, Marquita N


Full Text : http://www.dtic.mil/get-tr-doc/pdf?AD=ADA606936


Report Date : 11 Nov 2013


Pagination or Media Count : 30


Abstract : This document is the Final Report of the AMIGO Clinical Study: Attrition rates among Military beneficiaries undergoing Intensive Group Outpatient pre-diabetes care funded by AFMSA SG5I. This Final Report discusses the challenges that led to the early closure of the study along with lessons learned and future recommendations. The purpose of this study was to decrease the incidence of progression from pre-diabetes to diabetes by evaluating the impact a lifestyle coach has on a pre-diabetic patients adherence to a lifestyle education program and resultant improvement of lab values associated with their pre-diabetes diagnosis. The hypothesis was that a patient s adherence/completion of a diabetes prevention program and improvement of their pertinent laboratory values would be directly affected by the involvement of a personalized lifestyle coach. The AMIGO study was unable to evaluate the impact a lifestyle coach has on a pre-diabetic patients adherence to a lifestyle education program and did not reveal any statistical or clinically significant outcomes regarding lab value results of the intervention. It did result in lessons learned and provided a fundamental understanding of exactly what and moreover who is needed for program and study success which may prove to be beneficial for future researchers.


Descriptors :   *DIABETES , *OUTPATIENT CLINICS , ATTRITION , CLINICAL MEDICINE , CLOSURES , EDUCATION , INTERVENTION , LESSONS LEARNED , PATIENTS , PREVENTION , REPORTS , STATISTICS


Subject Categories : Medicine and Medical Research


Distribution Statement : APPROVED FOR PUBLIC RELEASE